Research articles & guides

Skin collagen falls by around 30% in the five years after menopause, and it tracks estrogen loss more closely than it tracks age. That single fact reframes almost every anti-aging peptide claim aimed at women.

These blends are sold on the strength of their best-known ingredient. Here is the evidence for each of the three or four compounds inside, scored separately, including the route problem nobody mentions.

A peptide causes hot flushes, and it was proven by giving it to women and watching them flush. The drugs that finally treat them are not peptides at all, which is the part the marketing gets backwards.

Three peptides have real trial evidence in menopausal women, because the indication is a women's condition. For almost everything else marketed at this life stage, the honest answer is that nobody has looked.

Lyophilized powder holds for years. The moment it goes into solution, a clock starts. Here is the arithmetic, the temperatures, and the handling errors that quietly cost potency.

The 'stacking' conversation, translated into research terms, with the compliance and evidence caveats that come with it.

What research peptides are, how the evidence is graded on this site, and why the sex-disaggregated question sits at the center of all of it.

Single, dual, and triple receptor agonists, compared on target, trial stage, and how much of the human data involved women.

The two headline tissue-repair peptides, side by side, on mechanism, evidence stage, and the female-data question.

Two Russian-developed neuropeptides, often mentioned together. How their studied mechanisms and evidence differ, and what neither has answered for women.

Nootropic peptides are among the most hyped and least sex-studied. What the literature actually shows.

Thymic peptides and antimicrobial fragments studied for immune signaling, and how the female evidence stacks up.

Selank, Semax, and DSIP appear across the calm-and-focus conversation. Here is the evidence, and the female-data gap.

Bone loss accelerates around menopause, yet the peptide research rarely centers the women most affected.

The aging-research peptides carry some of the boldest claims and some of the thinnest human data. A grounded map.

The two most-discussed recovery peptides have deep preclinical files and shallow human, sex-stratified ones.

BPC-157 and anti-inflammatory fragments dominate the gut-healing conversation, on almost entirely preclinical, male-weighted data.

DSIP and related compounds have been studied for sleep signaling, rarely with attention to sex.

The incretin class has the strongest human data on this site. What that means for women, and where cycle-specific questions remain.

Cosmetic peptides are one of the few areas with female-heavy human research. Here is what that evidence supports.

Copper peptides, GHK, and signaling compounds studied for the follicle, and how female-pattern data compares.

The one area where a peptide reached approval specifically in women, and the wider research context around it.

PCOS is common and under-served by research. Here is what the metabolic and reproductive peptide literature does and does not address.

A sober look at the compounds discussed for the menopausal transition, and how little of the research was designed to answer it.

An exercise-induced signaling peptide studied for adipose and energy-expenditure biology.

A proline-containing dipeptide studied for neurotrophic-factor signaling, with a male-weighted evidence base.

One of the rare compounds with a female-majority literature, and what that large evidence base does and does not settle.

A triple monoamine-reuptake inhibitor studied in appetite and energy-balance research models.

A long-acting amylin analogue studied for satiety signaling, often paired with GLP-1 agonists in metabolic research.

A mitochondrial-derived peptide studied for metabolic and exercise signaling. The human and female records are still early.

A neuropeptide at the top of the reproductive cascade, studied directly in women within reproductive medicine.

An investigational GIP/GLP-1/glucagon triple agonist in active trials that enrolled women. What the emerging data shows.

A coenzyme central to mitochondrial metabolism, studied in aging research. Where the human evidence is, and where sex-specific data isn't.

A peptide preparation studied for neurotrophic and neuroprotective signaling, with clinical use abroad and uneven sex reporting.

An angiotensin-IV-derived compound studied for synaptogenesis. Early, preclinical, and without sex-stratified human data.

A long-acting GHRH analogue studied for the somatotropic axis. The circulating dose conventions come from male-weighted work.

An early growth-hormone-releasing peptide studied for GH release and appetite signaling, with a male-weighted record.

A melanocortin agonist studied for pigmentation signaling. Popular interest runs well ahead of the controlled evidence, especially in women.

FDA-approved for HIV-associated lipodystrophy, its clinical program included women, which sets it apart from most research secretagogues.

A modified GH fragment studied for lipolytic signaling. The human record is limited, and the female record more so.

A thymic immune-signaling peptide with genuine clinical use abroad. What that means, and where the female-specific record still thins out.

Delta sleep-inducing peptide has been studied for sleep and stress signaling for decades, almost never by sex.

A rare peptide with an FDA-approved female indication. A worked example of reading direct female evidence without overstating it.

A widely used recovery research peptide with an almost entirely preclinical, largely male evidence base.

A GLP-1 receptor agonist backed by large trials that included thousands of women. Inclusion is not the same as sex-specific analysis.

A GIP/GLP-1 dual agonist with large human trials that enrolled women. Where the female data is genuinely strong, and where cycle-specific questions remain open.

One of the cleaner ghrelin-receptor research peptides. The dosing conventions are male-weighted, and the female-specific evidence is largely absent.

An oral ghrelin-mimetic secretagogue studied for the GH/IGF-1 axis. What the research covers, and the female-specific questions it doesn't.

A tetrapeptide studied for telomerase and pineal regulation. Strong claims, thin human data, and a female record thinner still.

A synthetic tuftsin analogue studied for anxiety and immune signaling. The literature rarely reports outcomes by sex, and that gap is the point.

An ACTH-derived neuropeptide with real preclinical depth and almost no sex-stratified data. Here is what the research shows and what it leaves open for women.

Ipamorelin, CJC-1295, tesamorelin, the dosing conventions come from studies that were mostly male. Estrogen is the reason that matters.

GHK-Cu is an exception to the rule of this site, a compound whose most relevant human research was done largely in women. Here's what that does and doesn't buy you.

The GLP-1 trials enrolled thousands of women. They rarely asked the questions that are specific to a woman's cycle. Here's the line between the two.

A worked example of how to evaluate a popular peptide when the evidence base is entirely preclinical, and entirely male.

A COA is the difference between a tested research compound and a claim on a label. Here is what each line actually tells you, what the headline purity figure quietly leaves out, and how to tie the document to the vial in your hand.

For decades, research protected women by excluding them. The gap that policy created is the reason a database like this has to exist.